UPA AOD9604

AOD-9604 is a synthetic peptide fragment of human growth hormone (HGH), composed of amino acids 176–191 at the C-terminal end of the HGH molecule. Researchers discovered that this specific sequence is responsible for much of HGH’s fat-burning activity without its growth-promoting effects.

Why It Was Developed

Developed by (Metabolic Pharmaceuticals Ltd), which is currently undergoing phase II clinical trials. AOD-9604 is a synthetic peptide based on a peptide derived from the Cterminus of the human growth hormone (GH).

It’s main mechanistic outcomes are

→ Targeted fat loss: Designed to promote lipolysis (fat breakdown) and inhibit lipogenesis (fat formation).
→ Safety advantage: Unlike HGH, AOD-9604 does not significantly impact IGF-1, insulin sensitivity, or blood sugar regulation 
→ Therapeutic potential: Initially investigated as an anti-obesity drug, it has since gained attention in the wellness and peptide therapy communities for weight loss and metabolic health.

Halford, Jason CG. “Obesity drugs in clinical development.” Current Opinion in Investigational Drugs 7.4 (2006): 312.

How AOD-9604 Works

AOD-9604 was designed to replicate the lipolytic (fat-burning) properties of human growth hormone while removing its growth and insulin-related activity. It acts primarily on fat metabolism pathways, making it highly specific compared to HGH.

Mechanisms of Action

→ Stimulates lipolysis: Enhances the breakdown of stored fat into free fatty acids, which can then be used for energy 

→ Inhibits lipogenesis: Suppresses the enzymes responsible for creating new fat tissue, reducing the body’s tendency to store excess energy as fat

→ Promotes fat oxidation: Encourages the body to burn fat as fuel, especially in combination with calorie control and exercise.

→ No IGF-1 or glucose disruption: Unlike HGH, AOD-9604 does not significantly increase IGF-1 or negatively affect insulin sensitivity, making it a safer candidate for metabolic regulation 

Benefits of AOD-9604

When dosed consistently, AOD-9604 provides targeted fat-burning and metabolic support without the systemic hormonal risks seen with full-length HGH.

Fat Loss and Body Composition

→ Accelerates fat breakdown: Stimulates lipolysis, helping release stored fatty acids for energy
→ Prevents fat storage: Inhibits lipogenesis, reducing the body’s ability to store new fat 
→ Targets abdominal/visceral fat: Clinical data suggests activity in reducing stubborn central fat, which is linked to metabolic risk.

Metabolic Health

→ Neutral on glucose control: Unlike HGH, AOD-9604 does not negatively impact insulin sensitivity or fasting blood glucose.
→ Improves lipid metabolism: Some evidence points to better cholesterol and triglyceride regulation in obese individuals.

Joint and Recovery Benefits

→ Cartilage regeneration: Early data suggests possible joint-protective properties, making it a potential therapeutic candidate for osteoarthritis and cartilage repair 

Advantages Over Other Fat-Loss Therapies

→ No IGF-1 elevation: Avoids risks of acromegaly or unwanted tissue growth.
→ Non-stimulant: Suitable for individuals sensitive to caffeine or thermogenics.
→ Safe profile: Clinical trials show AOD-9604 is well tolerated with a side-effect rate similar to placebo.